|
Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma Clinical research trials and Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma. Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma clinical trial. Participants oftentimes recieve the most expert healthcare available for their Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma  Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
For Condition: stage 1 multiple myeloma,stage 2 multiple myeloma,stage 3 multiple myeloma
Status: No longer recruiting
Sponsor(s): Eastern Cooperative Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether combination chemotherapy plus interferon alfa is more effective than combination chemotherapy alone in treating patients with multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without interferon alfa in treating patients who have previously untreated stage I, stage II, or stage III multiple myeloma.
Details: OBJECTIVES: - Compare the response rate, time to response, duration of response, and survival in patients with previously untreated multiple myeloma treated with vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) alone vs VBMCP alternating first with high-dose cyclophosphamide and then with interferon alfa in patients with previously untreated multiple myeloma. - Compare the toxicity of these regimens in these patients. - Determine whether ancillary laboratory studies on companion protocol E-3A93 predict response and survival on this protocol. OUTLINE: This is a randomized study. Patients are stratified according to creatinine (less than 2.0 vs 2.0 mg/dL or greater), performance status (0-1 vs 2-4), plasma cell labeling index (2% or more vs less than 2% vs approved unknown/not interpretable), and beta-2 microglobulin (4 micrograms/dL or greater vs less than 4 micrograms/dL vs approved unknown/not interpretable). - Induction: Patients receive vincristine IV, carmustine IV, and cyclophosphamide (CTX) IV on day 1; oral melphalan on days 1-4; and oral prednisone on days 1-7 (VBMCP). Treatment continues every 5 weeks for 2 courses. - Patients are then randomized to 1 of 2 treatment arms. - Arm I: Patients receive VBMCP as in induction. Courses repeat every 5 weeks. - Arm II: Courses 1-3 each last 5 weeks, while subsequent courses each last 3 weeks. During courses 1 and 3, patients receive oral prednisone and high-dose CTX IV on days 1-4 and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. Patients receive VBMCP during course 2 and all subsequent even-numbered courses. Patients receive interferon alfa (IFN-A) SC three times a week for 10 doses during course 5 and all subsequent odd-numbered courses. The last dose for each course of IFN-A is administered concurrently with day 1 of course 6 and subsequent courses of VBMCP. Patients continue to receive alternating courses of VBMCP and IFN-A. After documentation of plateau, patients receive 2 additional courses of VBMCP (arm I) or 2 additional courses of VBMCP alternating with 2 courses of IFN-A (arm II) in the absence of disease progression. Treatment for arms I and II continues for 1-2 years in the absence of a plateau state plus 2 additional courses of VBMCP (arm I) or 2 courses each of VBMCP and IFN-A (arm II); disease progression; or unacceptable toxicity. Patients undergo observation beginning after completion of the 2 post-plateau courses and continuing in the absence of disease progression. Patients with disease progression after 3 months on observation receive reinduction comprising the consolidation regimen to which they were originally randomized. Reinduction continues in the absence of disease progression. PROJECTED ACCRUAL: A total of 289 patients will be accrued for this study within approximately 8 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of previously untreated, stage I-III multiple myeloma confirmed by: - Bone marrow plasmacytosis with at least 10% plasma cells or sheets of plasma cells or biopsy-proven plasmacytoma - At least 1 of the following: - M-protein in serum or urine - Osteolytic lesions on radiograph (generalized osteoporosis qualifies only if bone marrow aspirate contains at least 20% plasma cells) - Measurable disease - Serum M-protein at least 1.0 g/dL by serum protein electrophoresis - Urine M-protein (light chain) excretion greater than 200 mg/24 hours by urine protein electrophoresis - Biopsy-proven, measurable plasmacytoma(s) of soft tissue - Bone marrow plasmacytosis of at least 20% - No smoldering multiple myeloma - No nonsecretory myeloma - No localized plasmacytomas - No monoclonal gammopathy of undetermined significance - No primary systemic amyloidosis - No cord compression or CNS complication unless controlled by appropriate therapy - Concurrent registration on the ancillary laboratory protocol E-3A93 required except for participants from South African institutions PATIENT CHARACTERISTICS: Age: - 18 and over - Patients age 70 and over eligible if considered able to tolerate study therapy Performance status: - Under age 70: Known EGOG performance status - Age 70 and over: ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Absolute neutrophil count at least 1,000/mm3 - Platelet count at least 50,000/mm3 - No thrombophlebitis within the past 6 months Hepatic: - Bilirubin no greater than 2.0 mg/dL - SGOT no greater than 2.5 times upper limit of normal (ULN) - Alkaline phosphatase no greater than 2.5 times ULN Renal: - Creatinine no greater than 5.0 mg/dL - No renal disease - No hyperuricemia unless controlled by appropriate therapy Cardiovascular: - No myocardial infarction within the past 6 months - No hypertension requiring treatment other than diuretics and/or beta blockers, angiotensin converting enzyme inhibitors, or calcium channel blockers - Blood pressure greater than 140/90 mm Hg must be treated and maintained below 170/100 mm Hg on antihypertensives - No significant arrhythmia within the past 3 months, i.e.: - Sustained atrial or ventricular arrhythmia requiring antiarrhythmic drugs - Documented multifocal premature ventricular contractions requiring therapy - Ongoing requirement for antiarrhythmia drugs except digoxin to control the ventricular rate of atrial fibrillation that has been chronic for more than 1 year - Ejection fraction normal by echocardiogram or MUGA scan if history of congestive heart failure or myocardial infarction - No angina requiring nitrates or beta blockers Pulmonary: - No pulmonary emboli within the past 6 months Other: - No AIDS - No concurrent reversible condition (e.g., infection, hyperviscosity syndrome) unless controlled by appropriate therapy - No other malignancy within the past 5 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy Endocrine therapy: - Concurrent corticosteroids for hypercalcemia allowed Radiotherapy: - No prior radiotherapy to more than 15% of bone marrow - Concurrent radiotherapy allowed if delay of systemic therapy would pose undue risk to patient Surgery: - More than 5 years since prior surgery for other cancer Other: - See Cardiovascular - Concurrent bisphosphonates or other agents for hypercalcemia allowed - No concurrent anticoagulants
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertKyle, Study Chair, Mayo Clinic Cancer Center
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
United States
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61602
United States
Additional Information:
Study ID Numbers: CDR0000063435; E-5A93
Study Start Date:
Record last reviewed: March 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002556
Other Stage 3 Multiple Myeloma Studies:
1. Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
2. Rituximab in Treating Patients With Multiple Myeloma
3. Phase II Study of R115777 in Patients With Relapsed or Refractory Multiple Myeloma
4. Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
5. Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Related Studies:
Other stage 3 multiple myeloma Clinical Trials
Other Wisconsin Clinical Trials
Other Green Bay Clinical Trials
Combination Chemotherapy With or Without Interferon alfa in Treating Patients With Previously Untreated Multiple Myeloma
|
|
|
|
|
|
|
|
